Biomarkers for dementia in Latin American countries: Gaps and opportunities

Mario A. Parra; Paulina Orellana; Tomas Leon; Cabello G. Victoria; Fernando Henriquez; Rodrigo Gomez; Constanza Avalos; Andres Damian; Andrea Slachevsky; Agustin Ibañez; Henrik Zetterberg; Betty M. Tijms; Jennifer S. Yokoyama; Stefanie D. Piña-Escudero; J. Nicholas Cochran; Diana L. Matallana; Daisy Acosta; Ricardo Allegri; Bianca P. Arias-Suárez; Bernardo Barra; Maria Isabel Behrens; Sonia M.D. Brucki; Geraldo Busatto; Paulo Caramelli; Sheila Castro-Suarez; Valeria Contreras; Nilton Custodio; Sergio Dansilio; Myriam De la Cruz-Puebla; Leonardo Cruz de Souza; Monica M. Diaz; Lissette Duque; Gonzalo A. Farías; Sergio T. Ferreira; Nahuel Magrath Guimet; Ana Kmaid; David Lira; Francisco Lopera; Beatriz Mar Meza; Eliane C. Miotto; Ricardo Nitrini; Alberto Nuñez; Santiago O'Neill; John Ochoa; Maritza Pintado-Caipa; Elisa de Paula França Resende; Shannon Risacher; Luz Angela Rojas; Valentina Sabaj; Lucas Schilling; Allis F. Sellek; Ana Sosa; Leonel T. Takada; Antonio L. Teixeira; Martha Unaucho-Pilalumbo; Claudia Duran-Aniotz

doi:10.1002/alz.12757

Biomarkers for dementia in Latin American countries: Gaps and opportunities

Mario A. Parra, Paulina Orellana, Tomas Leon, Cabello G. Victoria, Fernando Henriquez, Rodrigo Gomez, Constanza Avalos, Andres Damian, Andrea Slachevsky, Agustin Ibañez, Henrik Zetterberg, Betty M. Tijms, Jennifer S. Yokoyama, Stefanie D. Piña-Escudero, J. Nicholas Cochran, Diana L. Matallana, Daisy Acosta, Ricardo Allegri, Bianca P. Arias-Suárez, Bernardo BarraMaria Isabel Behrens, Sonia M.D. Brucki, Geraldo Busatto, Paulo Caramelli, Sheila Castro-Suarez, Valeria Contreras, Nilton Custodio, Sergio Dansilio, Myriam De la Cruz-Puebla, Leonardo Cruz de Souza, Monica M. Diaz, Lissette Duque, Gonzalo A. Farías, Sergio T. Ferreira, Nahuel Magrath Guimet, Ana Kmaid, David Lira, Francisco Lopera, Beatriz Mar Meza, Eliane C. Miotto, Ricardo Nitrini, Alberto Nuñez, Santiago O'Neill, John Ochoa, Maritza Pintado-Caipa, Elisa de Paula França Resende, Shannon Risacher, Luz Angela Rojas, Valentina Sabaj, Lucas Schilling, Allis F. Sellek, Ana Sosa, Leonel T. Takada, Antonio L. Teixeira, Martha Unaucho-Pilalumbo, Claudia Duran-Aniotz

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Limited knowledge on dementia biomarkers in Latin American and Caribbean (LAC) countries remains a serious barrier. Here, we reported a survey to explore the ongoing work, needs, interests, potential barriers, and opportunities for future studies related to biomarkers. The results show that neuroimaging is the most used biomarker (73%), followed by genetic studies (40%), peripheral fluids biomarkers (31%), and cerebrospinal fluid biomarkers (29%). Regarding barriers in LAC, lack of funding appears to undermine the implementation of biomarkers in clinical or research settings, followed by insufficient infrastructure and training. The survey revealed that despite the above barriers, the region holds a great potential to advance dementia biomarkers research. Considering the unique contributions that LAC could make to this growing field, we highlight the urgent need to expand biomarker research. These insights allowed us to propose an action plan that addresses the recommendations for a biomarker framework recently proposed by regional experts.

Original language	English
Pages (from-to)	721-735
Number of pages	15
Journal	Alzheimer's and Dementia
Volume	19
Issue number	2
DOIs	https://doi.org/10.1002/alz.12757
State	Published - Feb 2023
Externally published	Yes

Access to Document

10.1002/alz.12757

Cite this

Parra, M. A., Orellana, P., Leon, T., Victoria, C. G., Henriquez, F., Gomez, R., Avalos, C., Damian, A., Slachevsky, A., Ibañez, A., Zetterberg, H., Tijms, B. M., Yokoyama, J. S., Piña-Escudero, S. D., Cochran, J. N., Matallana, D. L., Acosta, D., Allegri, R., Arias-Suárez, B. P., ... Duran-Aniotz, C. (2023). Biomarkers for dementia in Latin American countries: Gaps and opportunities. Alzheimer's and Dementia, 19(2), 721-735. https://doi.org/10.1002/alz.12757

@article{7585442e5c834356970fa2501d47741e,

title = "Biomarkers for dementia in Latin American countries: Gaps and opportunities",

abstract = "Limited knowledge on dementia biomarkers in Latin American and Caribbean (LAC) countries remains a serious barrier. Here, we reported a survey to explore the ongoing work, needs, interests, potential barriers, and opportunities for future studies related to biomarkers. The results show that neuroimaging is the most used biomarker (73%), followed by genetic studies (40%), peripheral fluids biomarkers (31%), and cerebrospinal fluid biomarkers (29%). Regarding barriers in LAC, lack of funding appears to undermine the implementation of biomarkers in clinical or research settings, followed by insufficient infrastructure and training. The survey revealed that despite the above barriers, the region holds a great potential to advance dementia biomarkers research. Considering the unique contributions that LAC could make to this growing field, we highlight the urgent need to expand biomarker research. These insights allowed us to propose an action plan that addresses the recommendations for a biomarker framework recently proposed by regional experts.",

author = "Parra, {Mario A.} and Paulina Orellana and Tomas Leon and Victoria, {Cabello G.} and Fernando Henriquez and Rodrigo Gomez and Constanza Avalos and Andres Damian and Andrea Slachevsky and Agustin Iba{\~n}ez and Henrik Zetterberg and Tijms, {Betty M.} and Yokoyama, {Jennifer S.} and Pi{\~n}a-Escudero, {Stefanie D.} and Cochran, {J. Nicholas} and Matallana, {Diana L.} and Daisy Acosta and Ricardo Allegri and Arias-Su{\'a}rez, {Bianca P.} and Bernardo Barra and Behrens, {Maria Isabel} and Brucki, {Sonia M.D.} and Geraldo Busatto and Paulo Caramelli and Sheila Castro-Suarez and Valeria Contreras and Nilton Custodio and Sergio Dansilio and {la Cruz-Puebla}, {Myriam De} and {de Souza}, {Leonardo Cruz} and Diaz, {Monica M.} and Lissette Duque and Far{\'i}as, {Gonzalo A.} and Ferreira, {Sergio T.} and Guimet, {Nahuel Magrath} and Ana Kmaid and David Lira and Francisco Lopera and Meza, {Beatriz Mar} and Miotto, {Eliane C.} and Ricardo Nitrini and Alberto Nu{\~n}ez and Santiago O'Neill and John Ochoa and Maritza Pintado-Caipa and Resende, {Elisa de Paula Fran{\c c}a} and Shannon Risacher and Rojas, {Luz Angela} and Valentina Sabaj and Lucas Schilling and Sellek, {Allis F.} and Ana Sosa and Takada, {Leonel T.} and Teixeira, {Antonio L.} and Martha Unaucho-Pilalumbo and Claudia Duran-Aniotz",

note = "Funding Information: We thank Sandro Casavilca-Zambrano, Gabriel Espinoza Coronel, Jose Carlos Huilca Flores, Pablo Martinez-Lage, Dongjun Yoo, and Fernando Lara Roquette, who participated in answering the survey. C.D.A. is partially supported by 2018-AARG-591107, ANID/FONDEF IDEA ID20I10152, ANID/FONDECYT Regular 1210622, and ANID/PIA/ANILLOS ACT210096. A.I. is supported by grants from CONICET; ANID/FONDECYT Regular (1210195 and 1210176); ANID/FONDAP (15150012); FONCYT-PICT 2017-1820; Takeda CW2680521; Sistema General de Regal{\'i}as (BPIN2018000100059), Universidad del Valle (CI 5316); Alzheimer's Association GBHI ALZ UK-20-639295; and the MULTI-PARTNER CONSORTIUM TO EXPAND DEMENTIA RESEARCH IN LATIN AMERICA (ReDLat, supported by National Institutes of Health, National Institutes of Aging [R01 AG057234], Alzheimer's Association [SG-20-725707], Rainwater Charitable foundation-Tau Consortium, and Global Brain Health Institute). M.I.B. is supported by ANID/Fondecyt Regular (1190958), ANID/FONDEF-IDEA (ID20I10252 and (ID19I10302), and ANID/Fondequip 2021. The contents of this publication are solely the responsibility of the authors and do not represent the official views of these Institutions. L.C.S. and P.C. hold a senior researcher grant (bolsa de produtividade em pesquisa) from CNPq, Brazil. STF is funded by the Brazilian agencies Conselho Nacional de Desenvolvimento Cient{\'i}fico e Tecnol{\'o}gico (CNPq), Funda{\c c}{\~a}o de Amparo {\`a} Pesquisa do Estado do Rio de Janeiro (FAPERJ), and National Institute for Translational Neuroscience. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen f{\"o}r Gamla Tj{\"a}narinnor, Hj{\"a}rnfonden, Sweden (#FO2019-0228), the European Union's Horizon 2020 research and innovation programme under the Marie Sk{\l}odowska-Curie grant agreement No 860197 (MIRIADE), European Union Joint Program for Neurodegenerative Disorders (JPND2021-00694), and the UK Dementia Research Institute at UCL. F.H. was supported by grants from ANID-Subdirecci{\'o}n de Capital Humano/Doctorado Nacional/2021- 21211349, Chile. Funding Information: LAC hosts unprecedented opportunities to advance biomarker development and validation globally. Our survey suggests that the region holds positive attitudes to embark on such developments. Respondents of this survey who are not currently using biomarkers reported their eagerness to incorporate “all biomarkers that they could work with.” Previous reports have characterized regional realities and provided action plans to tackle them. Here, we specifically aim to contribute to the biomarker framework proposed by the LAC‐CD's Knowledge to Action Plan, which includes: (1) Validation and implementation of harmonized protocols such as the A/T/N framework in LAC hubs. This survey provided evidence of centers that act as such hubs. (2) Strengthening of partnership with the Alzheimer's Association and the National Institutes of Health/National Institute on Aging (NIH/NIA) to improve regional grant proposals, expand funding opportunities and increase collaborative work among LAC‐CD members. This survey has contributed evidence on funding barriers and eagerness of respondents to engage in collaborative work. We have initiated discussions with leaders of the Neuroimaging and Biofluid Based Biomarkers Professional Interest Areas of ISTAART to set up regional biomarker networks and collaborative groups. (3) Introduction of complementary affordable biomarkers based on new assessments depending on the infrastructure available in each LAC country included in this study. The survey contributed evidence on laboratories where biofluid‐based biomarkers could be swiftly introduced or enhanced. We will invite these center and groups to join the LAC Biomarker Network to expand funding opportunities. (4) Improved understanding of the interplay of the genetic mechanisms, clinical phenotypes, and severity of neurodegenerative diseases. The survey provided valuable information that complements previous efforts from LAC‐CD and together they pave the way for future work on the above factors. There are ongoing initiatives that will contribute and further benefit from such work (ReDLat, NIH‐R01 consortia grants of biomarkers/epigenetics/linguistic, and LAC funding of new peripheral biomarkers). (5) Promotion of efforts via capacity building, implementation science, and translational research to support regional dementia plans; enhance the regional health systems{\textquoteright} infrastructure related to brain health; and facilitate future agreements with governments to increase the budget for dementia prevention, care, and research. We are confident that new collaborative initiatives currently considering the LAC region will soon materialize. 3 Funding Information: We thank Sandro Casavilca‐Zambrano, Gabriel Espinoza Coronel, Jose Carlos Huilca Flores, Pablo Martinez‐Lage, Dongjun Yoo, and Fernando Lara Roquette, who participated in answering the survey. C.D.A. is partially supported by 2018‐AARG‐591107, ANID/FONDEF IDEA ID20I10152, ANID/FONDECYT Regular 1210622, and ANID/PIA/ANILLOS ACT210096. A.I. is supported by grants from CONICET; ANID/FONDECYT Regular (1210195 and 1210176); ANID/FONDAP (15150012); FONCYT‐PICT 2017‐1820; Takeda CW2680521; Sistema General de Regal{\'i}as (BPIN2018000100059), Universidad del Valle (CI 5316); Alzheimer's Association GBHI ALZ UK‐20‐639295; and the MULTI‐PARTNER CONSORTIUM TO EXPAND DEMENTIA RESEARCH IN LATIN AMERICA (ReDLat, supported by National Institutes of Health, National Institutes of Aging [R01 AG057234], Alzheimer's Association [SG‐20‐725707], Rainwater Charitable foundation‐Tau Consortium, and Global Brain Health Institute). M.I.B. is supported by ANID/Fondecyt Regular (1190958), ANID/FONDEF‐IDEA (ID20I10252 and (ID19I10302), and ANID/Fondequip 2021. The contents of this publication are solely the responsibility of the authors and do not represent the official views of these Institutions. L.C.S. and P.C. hold a senior researcher grant (bolsa de produtividade em pesquisa) from CNPq, Brazil. STF is funded by the Brazilian agencies Conselho Nacional de Desenvolvimento Cient{\'i}fico e Tecnol{\'o}gico (CNPq), Funda{\c c}{\~a}o de Amparo {\`a} Pesquisa do Estado do Rio de Janeiro (FAPERJ), and National Institute for Translational Neuroscience. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018‐02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG‐720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809‐2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF‐21‐831376‐C, #ADSF‐21‐831381‐C and #ADSF‐21‐831377‐C), the Olav Thon Foundation, the Erling‐Persson Family Foundation, Stiftelsen f{\"o}r Gamla Tj{\"a}narinnor, Hj{\"a}rnfonden, Sweden (#FO2019‐0228), the European Union's Horizon 2020 research and innovation programme under the Marie Sk{\l}odowska‐Curie grant agreement No 860197 (MIRIADE), European Union Joint Program for Neurodegenerative Disorders (JPND2021‐00694), and the UK Dementia Research Institute at UCL. F.H. was supported by grants from ANID‐Subdirecci{\'o}n de Capital Humano/Doctorado Nacional/2021‐ 21211349, Chile. Publisher Copyright: {\textcopyright} 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",

year = "2023",

month = feb,

doi = "10.1002/alz.12757",

language = "English",

volume = "19",

pages = "721--735",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "John Wiley & Sons Inc.",

number = "2",

}

Parra, MA, Orellana, P, Leon, T, Victoria, CG, Henriquez, F, Gomez, R, Avalos, C, Damian, A, Slachevsky, A, Ibañez, A, Zetterberg, H, Tijms, BM, Yokoyama, JS, Piña-Escudero, SD, Cochran, JN, Matallana, DL, Acosta, D, Allegri, R, Arias-Suárez, BP, Barra, B, Behrens, MI, Brucki, SMD, Busatto, G, Caramelli, P, Castro-Suarez, S, Contreras, V, Custodio, N, Dansilio, S, la Cruz-Puebla, MD, de Souza, LC, Diaz, MM, Duque, L, Farías, GA, Ferreira, ST, Guimet, NM, Kmaid, A, Lira, D, Lopera, F, Meza, BM, Miotto, EC, Nitrini, R, Nuñez, A, O'Neill, S, Ochoa, J, Pintado-Caipa, M, Resende, EDPF, Risacher, S, Rojas, LA, Sabaj, V, Schilling, L, Sellek, AF, Sosa, A, Takada, LT, Teixeira, AL, Unaucho-Pilalumbo, M & Duran-Aniotz, C 2023, 'Biomarkers for dementia in Latin American countries: Gaps and opportunities', Alzheimer's and Dementia, vol. 19, no. 2, pp. 721-735. https://doi.org/10.1002/alz.12757

TY - JOUR

T1 - Biomarkers for dementia in Latin American countries

T2 - Gaps and opportunities

AU - Parra, Mario A.

AU - Orellana, Paulina

AU - Leon, Tomas

AU - Victoria, Cabello G.

AU - Henriquez, Fernando

AU - Gomez, Rodrigo

AU - Avalos, Constanza

AU - Damian, Andres

AU - Slachevsky, Andrea

AU - Ibañez, Agustin

AU - Zetterberg, Henrik

AU - Tijms, Betty M.

AU - Yokoyama, Jennifer S.

AU - Piña-Escudero, Stefanie D.

AU - Cochran, J. Nicholas

AU - Matallana, Diana L.

AU - Acosta, Daisy

AU - Allegri, Ricardo

AU - Arias-Suárez, Bianca P.

AU - Barra, Bernardo

AU - Behrens, Maria Isabel

AU - Brucki, Sonia M.D.

AU - Busatto, Geraldo

AU - Caramelli, Paulo

AU - Castro-Suarez, Sheila

AU - Contreras, Valeria

AU - Custodio, Nilton

AU - Dansilio, Sergio

AU - la Cruz-Puebla, Myriam De

AU - de Souza, Leonardo Cruz

AU - Diaz, Monica M.

AU - Duque, Lissette

AU - Farías, Gonzalo A.

AU - Ferreira, Sergio T.

AU - Guimet, Nahuel Magrath

AU - Kmaid, Ana

AU - Lira, David

AU - Lopera, Francisco

AU - Meza, Beatriz Mar

AU - Miotto, Eliane C.

AU - Nitrini, Ricardo

AU - Nuñez, Alberto

AU - O'Neill, Santiago

AU - Ochoa, John

AU - Pintado-Caipa, Maritza

AU - Resende, Elisa de Paula França

AU - Risacher, Shannon

AU - Rojas, Luz Angela

AU - Sabaj, Valentina

AU - Schilling, Lucas

AU - Sellek, Allis F.

AU - Sosa, Ana

AU - Takada, Leonel T.

AU - Teixeira, Antonio L.

AU - Unaucho-Pilalumbo, Martha

AU - Duran-Aniotz, Claudia

N1 - Funding Information: We thank Sandro Casavilca-Zambrano, Gabriel Espinoza Coronel, Jose Carlos Huilca Flores, Pablo Martinez-Lage, Dongjun Yoo, and Fernando Lara Roquette, who participated in answering the survey. C.D.A. is partially supported by 2018-AARG-591107, ANID/FONDEF IDEA ID20I10152, ANID/FONDECYT Regular 1210622, and ANID/PIA/ANILLOS ACT210096. A.I. is supported by grants from CONICET; ANID/FONDECYT Regular (1210195 and 1210176); ANID/FONDAP (15150012); FONCYT-PICT 2017-1820; Takeda CW2680521; Sistema General de Regalías (BPIN2018000100059), Universidad del Valle (CI 5316); Alzheimer's Association GBHI ALZ UK-20-639295; and the MULTI-PARTNER CONSORTIUM TO EXPAND DEMENTIA RESEARCH IN LATIN AMERICA (ReDLat, supported by National Institutes of Health, National Institutes of Aging [R01 AG057234], Alzheimer's Association [SG-20-725707], Rainwater Charitable foundation-Tau Consortium, and Global Brain Health Institute). M.I.B. is supported by ANID/Fondecyt Regular (1190958), ANID/FONDEF-IDEA (ID20I10252 and (ID19I10302), and ANID/Fondequip 2021. The contents of this publication are solely the responsibility of the authors and do not represent the official views of these Institutions. L.C.S. and P.C. hold a senior researcher grant (bolsa de produtividade em pesquisa) from CNPq, Brazil. STF is funded by the Brazilian agencies Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), and National Institute for Translational Neuroscience. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), European Union Joint Program for Neurodegenerative Disorders (JPND2021-00694), and the UK Dementia Research Institute at UCL. F.H. was supported by grants from ANID-Subdirección de Capital Humano/Doctorado Nacional/2021- 21211349, Chile. Funding Information: LAC hosts unprecedented opportunities to advance biomarker development and validation globally. Our survey suggests that the region holds positive attitudes to embark on such developments. Respondents of this survey who are not currently using biomarkers reported their eagerness to incorporate “all biomarkers that they could work with.” Previous reports have characterized regional realities and provided action plans to tackle them. Here, we specifically aim to contribute to the biomarker framework proposed by the LAC‐CD's Knowledge to Action Plan, which includes: (1) Validation and implementation of harmonized protocols such as the A/T/N framework in LAC hubs. This survey provided evidence of centers that act as such hubs. (2) Strengthening of partnership with the Alzheimer's Association and the National Institutes of Health/National Institute on Aging (NIH/NIA) to improve regional grant proposals, expand funding opportunities and increase collaborative work among LAC‐CD members. This survey has contributed evidence on funding barriers and eagerness of respondents to engage in collaborative work. We have initiated discussions with leaders of the Neuroimaging and Biofluid Based Biomarkers Professional Interest Areas of ISTAART to set up regional biomarker networks and collaborative groups. (3) Introduction of complementary affordable biomarkers based on new assessments depending on the infrastructure available in each LAC country included in this study. The survey contributed evidence on laboratories where biofluid‐based biomarkers could be swiftly introduced or enhanced. We will invite these center and groups to join the LAC Biomarker Network to expand funding opportunities. (4) Improved understanding of the interplay of the genetic mechanisms, clinical phenotypes, and severity of neurodegenerative diseases. The survey provided valuable information that complements previous efforts from LAC‐CD and together they pave the way for future work on the above factors. There are ongoing initiatives that will contribute and further benefit from such work (ReDLat, NIH‐R01 consortia grants of biomarkers/epigenetics/linguistic, and LAC funding of new peripheral biomarkers). (5) Promotion of efforts via capacity building, implementation science, and translational research to support regional dementia plans; enhance the regional health systems’ infrastructure related to brain health; and facilitate future agreements with governments to increase the budget for dementia prevention, care, and research. We are confident that new collaborative initiatives currently considering the LAC region will soon materialize. 3 Funding Information: We thank Sandro Casavilca‐Zambrano, Gabriel Espinoza Coronel, Jose Carlos Huilca Flores, Pablo Martinez‐Lage, Dongjun Yoo, and Fernando Lara Roquette, who participated in answering the survey. C.D.A. is partially supported by 2018‐AARG‐591107, ANID/FONDEF IDEA ID20I10152, ANID/FONDECYT Regular 1210622, and ANID/PIA/ANILLOS ACT210096. A.I. is supported by grants from CONICET; ANID/FONDECYT Regular (1210195 and 1210176); ANID/FONDAP (15150012); FONCYT‐PICT 2017‐1820; Takeda CW2680521; Sistema General de Regalías (BPIN2018000100059), Universidad del Valle (CI 5316); Alzheimer's Association GBHI ALZ UK‐20‐639295; and the MULTI‐PARTNER CONSORTIUM TO EXPAND DEMENTIA RESEARCH IN LATIN AMERICA (ReDLat, supported by National Institutes of Health, National Institutes of Aging [R01 AG057234], Alzheimer's Association [SG‐20‐725707], Rainwater Charitable foundation‐Tau Consortium, and Global Brain Health Institute). M.I.B. is supported by ANID/Fondecyt Regular (1190958), ANID/FONDEF‐IDEA (ID20I10252 and (ID19I10302), and ANID/Fondequip 2021. The contents of this publication are solely the responsibility of the authors and do not represent the official views of these Institutions. L.C.S. and P.C. hold a senior researcher grant (bolsa de produtividade em pesquisa) from CNPq, Brazil. STF is funded by the Brazilian agencies Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), and National Institute for Translational Neuroscience. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018‐02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG‐720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809‐2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF‐21‐831376‐C, #ADSF‐21‐831381‐C and #ADSF‐21‐831377‐C), the Olav Thon Foundation, the Erling‐Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019‐0228), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska‐Curie grant agreement No 860197 (MIRIADE), European Union Joint Program for Neurodegenerative Disorders (JPND2021‐00694), and the UK Dementia Research Institute at UCL. F.H. was supported by grants from ANID‐Subdirección de Capital Humano/Doctorado Nacional/2021‐ 21211349, Chile. Publisher Copyright: © 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

PY - 2023/2

Y1 - 2023/2

N2 - Limited knowledge on dementia biomarkers in Latin American and Caribbean (LAC) countries remains a serious barrier. Here, we reported a survey to explore the ongoing work, needs, interests, potential barriers, and opportunities for future studies related to biomarkers. The results show that neuroimaging is the most used biomarker (73%), followed by genetic studies (40%), peripheral fluids biomarkers (31%), and cerebrospinal fluid biomarkers (29%). Regarding barriers in LAC, lack of funding appears to undermine the implementation of biomarkers in clinical or research settings, followed by insufficient infrastructure and training. The survey revealed that despite the above barriers, the region holds a great potential to advance dementia biomarkers research. Considering the unique contributions that LAC could make to this growing field, we highlight the urgent need to expand biomarker research. These insights allowed us to propose an action plan that addresses the recommendations for a biomarker framework recently proposed by regional experts.

AB - Limited knowledge on dementia biomarkers in Latin American and Caribbean (LAC) countries remains a serious barrier. Here, we reported a survey to explore the ongoing work, needs, interests, potential barriers, and opportunities for future studies related to biomarkers. The results show that neuroimaging is the most used biomarker (73%), followed by genetic studies (40%), peripheral fluids biomarkers (31%), and cerebrospinal fluid biomarkers (29%). Regarding barriers in LAC, lack of funding appears to undermine the implementation of biomarkers in clinical or research settings, followed by insufficient infrastructure and training. The survey revealed that despite the above barriers, the region holds a great potential to advance dementia biomarkers research. Considering the unique contributions that LAC could make to this growing field, we highlight the urgent need to expand biomarker research. These insights allowed us to propose an action plan that addresses the recommendations for a biomarker framework recently proposed by regional experts.

UR - http://www.scopus.com/inward/record.url?scp=85138014229&partnerID=8YFLogxK

U2 - 10.1002/alz.12757

DO - 10.1002/alz.12757

M3 - Article

C2 - 36098676

AN - SCOPUS:85138014229

SN - 1552-5260

VL - 19

SP - 721

EP - 735

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 2

ER -

Biomarkers for dementia in Latin American countries: Gaps and opportunities

Abstract

Access to Document

Fingerprint

Cite this